Earlier this year, the BBC reported that "HRT - Hormone Replacement Therapy - can shrink women's brains"1, after a study was published which showed that brain volume in women taking HRT was smaller in two key areas involved in thinking and memory. This comes in addition to earlier results from the Women's Health Initiative (WHI) Memory Study2 that linked HRT to an increased risk of memory loss and dementia, and an article in the Lancet3 which concluded that HRT "substantially increases the risk of dementia of any cause and cognitive* decline" (* memory, thinking and understanding). This adds to the growing body of evidence that the risks of HRT far outweigh any perceived benefits, evidence that Nutri Pharma feels needs to be brought to the attention of the 150, 000 women in Norway and millions of women across Europe who are still being prescribed this treatment.
Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women. However, the 2002 publication of a major study, the Women's Health Initiative (WHI), indicated increased risk for certain outcomes in older women, without increasing mortality. This sparked debate regarding potential benefits or harm of HRT. In an article published in the November 2009 issue of The American Journal of Medicine, researchers conducted a meta-analysis of the available data using Bayesian methods and concluded that HRT almost certainly decreases mortality in younger postmenopausal women.
For estrogen replacement to provide stroke protection, it likely must be given soon after levels drop because of menopause or surgical removal of the ovaries, scientists report in the Journal of Neuroscience. Animal studies indicate a "critical period" for estrogen replacement and that when therapy is delayed, estrogen receptors on brain cells are significantly diminished along with the neuroprotection estrogen typically conveys, according to scientists from the Medical College of Georgia, North China Coal Medical University and the University of Texas Health Sciences Center at San Antonio. "We looked at the controversy over whether estrogen is going to be beneficial after long periods without it and found the answer appears to be 'no, '" says Dr.
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. "Postmenopausal hormone treatment is associated with increased rates of benign breast biopsies, and early and late stages of cancer. Atypical ductal hyperplasia is associated with the use of postmenopausal hormone treatment and its rates have decreased with the decline in use of this treatment, " said researcher Tehillah Menes, M.D., who was the chief of breast service in the Department of Surgery at Elmhurst Hospital Center, New York, when this study was conducted.
Rates In Risk Factor For Breast Cancer, Atypical Ductal Hyperplasia, Fell In Line With Hormone Therapy Decline, US Study
Researchers in the US found that the decline in use of postmenopausal hormone therapy may partly explain the fall in incidence of a known risk factor for breast cancer, atypical ductal hyperplasia. They also said their findings support the idea that low and high grade breast cancers develop via different pathways and thereby clarify the role that hormone therapy may play in increasing the rates of breast cancer. The study was the work of first author Dr Tehillah Menes, and colleagues and is published in the November issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. Menes, who during the study was the chief of breast service in the Department of Surgery at Elmhurst Hospital Center, New York, told the press that: "Postmenopausal hormone treatment is associated with increased rates of benign breast biopsies, and early and late stages of cancer.
Women who have an early menopause are unlikely to have a long term increased risk of hip fractures associated with menopausal bone density weakening, according to a new study from The Australian National University. For decades medical practitioners have understood a link between menopause and a decrease in bone density. This has translated into clinicians advising women who had an early menopause that they are at particularly high risk of hip fracture - a common complaint amongst the elderly. The study, led by Associate Professor Emily Banks of the National Centre for Epidemiology and Population Health at ANU, has found that age is the main determinant of hip fracture and that among the elderly their age at menopause has little, if any, effect on hip fracture risk.